Article Text

PDF
CASE REPORT
Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history
  1. Jo-Hsuan Wu1,
  2. Jih-Shuin Jerng2 and
  3. Chien-Chia Su3
  1. 1 National Taiwan University College of Medicine, Taipei, Taiwan
  2. 2 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  3. 3 Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan
  1. Correspondence to Dr Jih-Shuin Jerng, jsjerng{at}ntu.edu.tw

Abstract

Carteolol, a non-selective beta-antagonist with a potential risk of severe bronchial constriction in patients with asthma, is one of the most commonly prescribed medication for managing ocular pressure in glaucoma. We present a case of a 24-year-old woman with a history of atopy but no known asthma who presented an insidious onset of clinical manifestations compatible with drug-induced asthma after the initiation of carteolol for ocular hypertension control. The patient developed progressive chest tightness and dyspnoea for 2 months before the pulmonary function test revealed a positive bronchoprovocation response. She reported significant improvement of respiratory symptoms within 2 weeks after the discontinuation of carteolol, and a negative provocation response was later confirmed by repeat pulmonary function test. In conclusion, eye drops with non-selective beta-antagonising effect can induce asthmatic symptoms in patients without a previous diagnosis of asthma and should be administered with caution in patients with associated risk factors.

  • glaucoma
  • unwanted effects/adverse reactions
  • asthma
  • drugs: respiratory system
  • contraindications and precautions
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors J-HW wrote the article and made substantial contributions to the conception and design of this article; C-CS and J-SJ made a critical assessment of the article. All authors have been involved in drafting the manuscript and revising it critically for important intellectual content. All authors read and approved the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.